日本政府官员：在三月家庭支出中看到一些消费复苏的迹象，消费者在食品支出方面仍然节俭。 ...

Group 1 - The Federal Reserve's upcoming interest rate decision is highly anticipated, with a 96.9% probability of maintaining current rates, indicating that the market has already priced in the expectation of no change [3] - The real focus lies in Fed Chair Powell's communication style; a hawkish tone could pressure the stock market, while a more dovish signal might boost market confidence [3] - Domestic consumption data from the recent May Day holiday shows 314 million travelers generating 180.27 billion yuan in spending, reflecting a year-on-year growth of 6.4% and 8.0%, which exceeds expectations and signals strong domestic demand [6] Group 2 - Political dynamics in the U.S. are creating uncertainty, as Pence's criticism of Trump highlights the deep divisions within American politics, which could lead to volatility in capital markets [8] - Concerns are rising in the domestic futures market, with reports suggesting that retail investors' positions are being closely monitored, indicating a level of anxiety among market participants [9] - A three-dimensional observation framework is suggested, focusing on the Fed's decision-making paths, the sustainability of domestic consumption recovery, and the tension between technical market adjustments and favorable policies [11] Group 3 - The interplay between the consumption surge during the May Day holiday and potential policy support may indicate resilience in the Chinese economy, suggesting a possible new breakthrough [13] - Maintaining independent thinking amidst information overload is emphasized as a crucial strategy for market participants to navigate through economic cycles [13]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with some companies showing significant profit growth while facing challenges from high inventory and pricing pressures. The outlook for 2025 appears more optimistic due to easing macroeconomic factors and supportive policies [3][5][6]. Group 1: Market Performance - The A-share market saw major indices rise, with the Chinese Medicine ETF (560080) increasing by 0.19% and trading volume exceeding 26 million yuan, indicating active trading [1]. - Among the 49 constituent stocks of the Chinese Medicine ETF, 24 reported positive net profit growth, representing approximately 49% of the total [3]. Group 2: Company Performance - Notable profit growth was observed in companies such as Jilin Aodong (+260%), Jiaying Pharmaceutical (+197%), and Buchang Pharmaceutical (+170%) [3]. - The financial performance of several companies showed varied results, with Jilin Aodong reporting a 27.7% decline in revenue but a 259.8% increase in net profit [4]. Group 3: Industry Outlook - The Chinese medicine industry is expected to face challenges in 2024 due to high baselines and inventory digestion, but a recovery is anticipated in 2025 as macroeconomic conditions improve [5]. - Policy support, including the March 2025 guidelines for enhancing Chinese medicine quality, is expected to stimulate innovation and improve market conditions [5][6]. Group 4: Valuation and Investment Opportunities - The current valuation of the Chinese Medicine Index is at a price-to-earnings ratio of 25.77, which is below the 74.1% threshold of the past decade, indicating a relatively low valuation [8]. - Investors are encouraged to consider the Chinese Medicine ETF (560080) for potential rebound opportunities in the market [10].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [50]. Core Insights - The chemical agents and blood products sectors showed outstanding performance in 2024, while the CXO and medical services (hospitals) sectors reported positive growth in both revenue and profit for Q1 2025 [4][5]. - As of April 30, 2025, among 467 selected A-share biopharmaceutical companies, 28 companies reported revenue growth exceeding 30% for 2024, while 50 companies had growth over 20% [4]. - In Q1 2025, 24 companies achieved revenue growth greater than 30%, and 100 companies reported profit growth exceeding 30% [4]. Summary by Sections Industry Performance - In 2024, the chemical agents and blood products sectors maintained positive growth in both revenue and profit [5]. - For Q1 2025, the CXO and medical services sectors also reported positive growth in revenue and profit [5]. Investment Strategy - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery" as key investment themes [7]. - Recommended companies for "innovation" include BeiGene, Dongcheng Pharmaceutical, and others [7]. - For "going global," companies like Mindray Medical and Sinopharm are highlighted [7]. - In "equipment upgrades," companies such as Mindray Medical and Aohua Medical are suggested [7]. - Under "consumption recovery," companies like Puri Eye Hospital and Tongce Medical are noted [7]. Key Companies to Watch - **Nocera Health**: Achieved revenue of 1.009 billion yuan in 2024, with a 49% year-on-year increase in sales of its core product, Obinutuzumab [8]. - **Sihuan Pharmaceutical**: Maintained a stable performance with core products continuing to grow [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products expected to accelerate profit growth [13]. - **Aibao Medical**: The launch of its self-developed ICL lens is expected to drive significant revenue growth [23]. Industry News Highlights - BeiGene's Sonrotoclax new drug application has been accepted for review [30]. - Novartis' Lutetium-177 injection has been accepted for a new indication in China [31]. - Fuhong Hanlin signed a licensing agreement with Sandoz for HLX13 [33]. - BeiGene won a patent dispute, strengthening its market position for its BTK inhibitor [34].

Core Insights - The Labor Day holiday consumption showed robust growth despite high base effects, indicating a recovery in consumer spending, particularly in the retail and tourism sectors [1][10] - Key retail and catering enterprises reported a year-on-year sales increase of 6.3%, up from 4.1% during the Spring Festival holiday, with tourism revenue also exceeding pre-pandemic levels [1][4] Consumption Trends by Category - Home appliances, automobiles, and communication equipment saw significant sales growth of 15.5%, 13.7%, and 10.5% respectively, driven by the "old for new" policy [2][11] - The catering sector experienced an 8.7% increase, benefiting from high consumer willingness to spend on experiential dining [2] - Jewelry sales improved due to lower base effects and fluctuating gold prices, with some brands reporting a shift from negative to positive growth [8] Regional Consumption Insights - Consumption growth was balanced across different city tiers, with key tourist cities performing strongly and lower-tier cities benefiting from increased foot traffic [3][9] - Major cities like Beijing and Shanghai outperformed the national average in consumption growth, supported by domestic tourism and favorable visa policies for inbound travelers [3][9] Tourism and Travel Data - Domestic tourism revenue grew by 8%, with total visitor numbers increasing by 6.4%, indicating a recovery to 123% of pre-pandemic levels [4][11] - Outbound travel saw a robust year-on-year growth of 21%, with Hong Kong and Macau leading the increase in inbound tourism [4] Industry Performance Highlights - The sports and leisure retail sector reported a 15% increase in sales, attributed to rising outdoor activities and favorable weather conditions [5] - The high-end liquor market faced challenges, with increased discounting in the mid-to-high price segments due to cautious consumer spending [6] - The restaurant sector showed varied performance, with some brands like Nayuki's Tea achieving significant growth in both dine-in and delivery sales [7] Box Office and Entertainment - The box office revenue during the holiday period fell sharply by 51% to CNY 747 million, primarily due to a lack of blockbuster films [8][11]

Core Insights - Yili's revenue and net profit have declined for the first time in 29 years, with 2024 revenue at 115.39 billion, down 8.24% year-on-year, and net profit at 8.45 billion, down 18.9% [2][3] - Liquid milk, the core revenue driver, saw a significant revenue drop of 10.5 billion, a decrease of 12% [2][3] - The company's chairman, Pan Gang, experienced a slight salary reduction from 21.79 million to 19.74 million amid the performance decline [2] Revenue Performance - Yili's total revenue for 2024 was 115.39 billion, a decrease of 8.24% year-on-year, with net profit at 8.45 billion, down 18.9% [3][6] - Liquid milk revenue fell to 75 billion, a decline of over 12%, while the cold drink segment also saw a significant drop, with revenue at 8.72 billion, down 18.41% [3][5] - The share of liquid milk in total revenue has decreased from over 75% in previous years to approximately 65% in 2024 [6] Strategic Challenges - Yili has been facing challenges in its core liquid milk business, which has historically driven growth [5][6] - The company has invested approximately 6.3 billion in the infant formula sector, acquiring a stake in Aoyou Dairy, but this segment has also shown declining revenue and profits [7][9] - Aoyou's revenue fell from 8.575 billion in 2021 to 7.382 billion in 2023, with net profit dropping significantly [9][11] Future Outlook - Despite current challenges, Pan Gang expressed confidence in a gradual recovery of the consumer market, anticipating a return to growth in 2025 [14] - Yili is exploring new product lines, including ready-to-drink tea and other food categories, although these currently contribute minimally to overall revenue [13][14] - The company believes there is still growth potential in the dairy market, particularly in lower-tier cities where consumption is expected to rise [14]

Investment Rating - The report maintains an "Accumulate" rating for the food and beverage industry [1]. Core Insights - The food and beverage industry is experiencing a demand bottoming out, with opportunities for differentiation in sub-segments [1]. - The report highlights the potential for recovery in the dairy sector, driven by policy support and supply-side adjustments [33][34]. - The overall industry is facing challenges such as weak demand and increased competition, but cost advantages are improving profitability for leading companies [39][52]. Summary by Sections 1. Dairy Products - The dairy sector is expected to see an upward cycle as impairment pressures are released, with upstream clearing expected to continue [33]. - In 2024 and Q1 2025, the dairy industry faced significant supply-demand imbalances, with fresh milk prices dropping to levels not seen since 2010 [11][16]. - Major dairy companies like Yili and Mengniu are showing signs of revenue improvement in Q1 2025, benefiting from cost reductions and inventory management [20][28]. 2. Condiments - The condiment sector is characterized by strong resilience among leading companies, with significant cost advantages boosting profitability [39]. - In 2024 and Q1 2025, the condiment industry faced weak demand, but leading companies like Haitian and Zhongju have shown revenue improvements due to internal adjustments [39][52]. - The report suggests focusing on companies that have successfully implemented channel reforms and cost management strategies [49][52]. 3. Soft Drinks - The soft drink sector is experiencing a slowdown in revenue growth, with significant differentiation among companies [39]. - The report notes that leading brands like Dongpeng are capitalizing on cost reductions and scale effects to improve profitability [20][39]. - The overall market is expected to see a gradual recovery, with attention on long-term growth potential in specific segments [39]. 4. Health Products - The health product sector is undergoing a transformation driven by new consumer trends, with online brands gaining traction [39]. - Companies like H&H Holdings and Xianle Health are expected to benefit from market recovery and new retail contributions [39]. - The report emphasizes the importance of identifying high-quality companies with new consumer genes for investment opportunities [39]. 5. Hong Kong Restaurant Sector - The restaurant sector in Hong Kong is anticipated to recover as consumption stimulus policies take effect [39]. - Companies like Haidilao are focusing on supply chain and cost management to enhance performance [39]. - The report suggests monitoring companies that are expanding their store networks and improving operational efficiency [39].

Group 1 - The central bank's recent monetary policy adjustments, including interest rate cuts and mortgage relaxations, have injected significant liquidity into the market, yet the market remains cautious around the 3344-point resistance level [3][4] - The U.S. Federal Reserve's decision to pause interest rate cuts was anticipated, but the mixed signals from Chairman Powell regarding inflation and potential future rate cuts have led to volatility in the dollar index and a surge in gold prices [3][4] - The technology sector is experiencing notable activity, particularly with the resurgence of the Hongmeng PC, which has positively impacted related stocks, although caution is advised regarding the sustainability of such trends [3][4] Group 2 - Consumer recovery indicators, such as the May holiday data, show promise, but there are concerns about the sustainability of certain "pseudo-influencer" brands that rely on subsidies [4] - The new energy vehicle sector is witnessing a rise in sales despite falling lithium prices, leading to improved profit margins for manufacturers [4] - Investment strategies suggest maintaining a balanced portfolio, with a focus on high-quality manufacturing and consumer sectors, while being cautious of market volatility [5]

推荐（维持） 证券研究报告 | 行业定期报告 2025 年 05 月 07 日 整体业绩平淡，龙头强者恒强 调味品及餐饮供应链 24 年及 25 年一季报回顾 消费品/食品饮料 24 年看，整体需求弱复苏，企业普遍梳理渠道减轻库存压力。受益于成本下 行，板块毛利率改善，但竞争加剧下费用率有所提升，企业盈利分化。合并 24Q4+25Q1 看，板块受制于需求弱复苏及餐饮平淡，收入端相对承压，但海 天为代表的龙头企业率先完成调整，业绩更优。25 年看，预计成本端平稳，行 业费用投放相对稳定，若收入端加速复苏，则板块盈利能力有望进一步改善。 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 143 | 2.8 | | (%) 食品饮料 | | 沪深300 | | 总市值（十亿元） 30 | 5074.1 | 6.0 | | 流通市值（十亿 20 | 4823.6 | 6.2 | | 元） | | | 行业指数 0 % 1m 6m 12m 绝对表现 2.6 5.1 8.3 相对表现 4.0 10.5 4.1 资料来源：公司数据、招商证券 -30 -20 -10 May/2 ...